Propanc Biopharma, Inc.
NASDAQPPCB (Propanc Biopharma) faces its May 22 earnings report after a bruising month — down 28% over thirty days and 11% on the week alone, with its RSI-14 at a deeply oversold 27.7. The price slide dominates the setup here. At $2.01 per share, the stock has given back most of its gains from earlier in the year, and the selling has been persistent rather than episodic — the momentum…
PPCB short interest collapses 96% in one day to 0.17% of float, falling from 560K shares.
Snapshot as of 29 Jun 2026
PPCB (Propanc Biopharma) faces its May 22 earnings report after a bruising month — down 28% over thirty days and 11% on the week alone, with its RSI-14 at a deeply oversold 27.7. The price slide dominates the setup…
Propanc Biopharma heads into its May 18 earnings release as one of the more volatile micro-cap biotechs on the Nasdaq calendar, with short interest surging and its stock price hitting new lows. The short interest story…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PPCB — free to start on ORTEX.
Sign up for free →Open PPCB on ORTEX